SCHEMBL30567719

CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCSC)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 7)

	gene	UniProt	supporting neighbours	confidence
▸	KEAP1	Q14145	1/20	0.55

▸	GLP1R	P43220	11/20	0.55

▸	CALCR	P30988	3/20	0.55

▸	CRHR1	P34998	1/20	0.54

▸	CRHR2	Q13324	1/20	0.54

▸	RXFP1	Q9HBX9	1/20	0.53

▸	CCKBR	P32239	1/20	0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30567726	0.93	GLP1R (0.58)	KEAP1GLP1RCALCRCRHR1CRHR2
SCHEMBL31182663	0.92	CALCR (0.63)	KEAP1GLP1RCALCRCRHR1CRHR2
SCHEMBL30903287	0.91	GLP1R (0.58)	GLP1R
SCHEMBL30435350	0.90	GLP1R (0.62)	KEAP1GLP1RCALCRCRHR1CRHR2
SCHEMBL30495685	0.90	CALCR (0.59)	KEAP1GLP1RCALCRCRHR1CRHR2
SCHEMBL30567777	0.89	PTH1R (0.61)	GLP1RCALCRCRHR1CRHR2
SCHEMBL31182947	0.89	CALCR (0.61)	GLP1RCALCRCRHR1CRHR2CCKBR
SCHEMBL30176478	0.89	PTH1R (0.62)	GLP1RCALCRCRHR1CRHR2CCKBR
SCHEMBL4380506	0.89	GLP1R (0.62)	KEAP1GLP1RCALCRCRHR1CRHR2
SCHEMBL31410833	0.89	TFPI (0.56)	KEAP1GLP1RCALCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20240277841-A2	HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE	NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT	2024-08-22	—	—	US	disclosed
US-20240024473-A1	HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE	PURDUE RESEARCH FOUNDATION (US)	2024-01-25	—	—	US	disclosed
CN-116601290-A	Human chimeric antigen receptor neutrophils, compositions, kits and methods of use	普渡研究基金会	2023-08-15	—	—	CN	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20240277841-A2	HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE	PBK, KIT, MYD88	KEAP1 3595/4885GLP1R 2288/4885CALCR 889/4885
US-20240024473-A1	HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE	PBK, KIT, MYD88	KEAP1 3595/4885GLP1R 2288/4885CALCR 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.